troglitazone has been researched along with Dunnigan Syndrome in 1 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Maraldi, NM | 1 |
| Capanni, C | 1 |
| Mattioli, E | 1 |
| Columbaro, M | 1 |
| Squarzoni, S | 1 |
| Parnaik, WK | 1 |
| Wehnert, M | 1 |
| Lattanzi, G | 1 |
1 other study available for troglitazone and Dunnigan Syndrome
| Article | Year |
|---|---|
A pathogenic mechanism leading to partial lipodistrophy and prospects for pharmacological treatment of insulin resistance syndrome.
Topics: Adipocytes; Body Fat Distribution; Cell Differentiation; Chromans; Humans; Insulin Resistance; Lamin | 2007 |